Reporte zur Charge GH96935

Symptomtext

Treatment of COVID-19; Treatment of COVID-19; dose 4:Pfizer/ Dose3,2: Moderna/ Dose 1: Janssen; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 53-year-old female patient (not pregnant) received BNT162b2 (BNT162B2 NOS), on 10Oct2022 as dose 4 (booster), single (Lot number: GH96935) at the age of 53 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 15Nov2021 as dose 2, single (Lot number: 048F21A), in left arm and on 11Jul2022 as dose 3 (booster), single (Lot number: 059M21A), in left arm for covid-19 immunisation; coviD-19 vaccine nrvv ad26 (jnj 78436735) (JANSSEN COVID-19 VACCINE), on 10Mar2021 as dose 1, single (Lot number: 1805022), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Anxiety" (unspecified if ongoing); "Osteoarthritis" (unspecified if ongoing); "cic" (unspecified if ongoing), notes: cic. Concomitant medication(s) included: LEXAPRO, start date: 01Jun2021; TRULANCE, start date: 01Oct2022. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 10Oct2022, outcome "unknown", described as "dose 4:Pfizer/ Dose3,2: Moderna/ Dose 1: Janssen"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jan2023, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19.